🔗 Share this article Patients Discontinuing Slimming Jabs Regain Pounds at a Quadrupled Rate Than Dieters Weight management involves long-term strategies. New research indicates that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who end traditional diet and exercise programs. Published data in a leading health publication demonstrates that while obese individuals frequently drop a large proportion of their total mass while on the medication, the weight comes back at an average rate of nearly a kilo each month once they quit. "Individuals purchasing these medications should be aware of the risk of fast rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb. That rate of recovery implies a return to starting mass within about 18 months. Analyzing Treatments The analysis, which looked at 37 of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with other pills. The team note that people who lose weight through lifestyle changes alone usually experience a more gradual creep back—perhaps 0.1 kg a month—post-intervention. The Reason for the Rapid Rebound Doctors suggest the mode of action of the drugs accounts for the accelerated rebound. GLP-1 drugs copy a natural hormone called GLP-1, which moderates appetite. "Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher. "Stopping of this medication results in hunger is uncontrolled, making excessive eating much more probable." An Ongoing Disease? Medical guidelines recommend the jabs for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications. A number of clinicians argue that, considering the likelihood of weight regain, the treatment is often long-term. This view is reinforced by pharmaceutical companies, who note that the findings "underscore the long-term character of obesity," akin to managing conditions like high blood pressure. Patient Testimonies People who have discontinued the jabs describe a powerful return of hunger. "I experienced something flipping and you become starving," said one woman. This difficulty is compounded if users have not adopted lasting lifestyle or habit changes during treatment. Significant Use Figures indicate that millions of adults in the UK have tried these injections in the last 12 months, with desire being substantial. Use is more common among females than men. The middle-aged age group shows the greatest usage rates. A large proportion obtain the drugs through private prescriptions rather than public health services. Finally, clinicians emphasize that while the jabs are powerful agents for weight loss, they are not a standalone solution and lasting health benefits hinges on combined behavioural management.
Weight management involves long-term strategies. New research indicates that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who end traditional diet and exercise programs. Published data in a leading health publication demonstrates that while obese individuals frequently drop a large proportion of their total mass while on the medication, the weight comes back at an average rate of nearly a kilo each month once they quit. "Individuals purchasing these medications should be aware of the risk of fast rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb. That rate of recovery implies a return to starting mass within about 18 months. Analyzing Treatments The analysis, which looked at 37 of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with other pills. The team note that people who lose weight through lifestyle changes alone usually experience a more gradual creep back—perhaps 0.1 kg a month—post-intervention. The Reason for the Rapid Rebound Doctors suggest the mode of action of the drugs accounts for the accelerated rebound. GLP-1 drugs copy a natural hormone called GLP-1, which moderates appetite. "Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher. "Stopping of this medication results in hunger is uncontrolled, making excessive eating much more probable." An Ongoing Disease? Medical guidelines recommend the jabs for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications. A number of clinicians argue that, considering the likelihood of weight regain, the treatment is often long-term. This view is reinforced by pharmaceutical companies, who note that the findings "underscore the long-term character of obesity," akin to managing conditions like high blood pressure. Patient Testimonies People who have discontinued the jabs describe a powerful return of hunger. "I experienced something flipping and you become starving," said one woman. This difficulty is compounded if users have not adopted lasting lifestyle or habit changes during treatment. Significant Use Figures indicate that millions of adults in the UK have tried these injections in the last 12 months, with desire being substantial. Use is more common among females than men. The middle-aged age group shows the greatest usage rates. A large proportion obtain the drugs through private prescriptions rather than public health services. Finally, clinicians emphasize that while the jabs are powerful agents for weight loss, they are not a standalone solution and lasting health benefits hinges on combined behavioural management.